SamuelAJacobsMD
Oncology • Pittsburgh, PABreast Cancer, Gastrointestinal Cancer, Hematologic Oncology
NSABP Foundation
Dr. Jacobs is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
5115 Centre Ave
Pittsburgh, PA 15232Phone+1 412-235-1020Fax+1 412-235-1030
Education & Training
National Institutes of Health Clinical CenterFellowship, Medical Oncology, 1974 - 1976
UPMC Medical EducationResidency, Internal Medicine, 1971 - 1973
University of Rochester School of Medicine and DentistryClass of 1971
Certifications & Licensure
PA State Medical License 1976 - 2024- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Top MD Consumers Checkbook
Clinical Trials
- Phase II Trial of CHOP-R Followed by Zevalin and Rituxan in Follicular Lymphoma Start of enrollment: 2003 Nov 01
Publications & Presentations
PubMed
- Effect of cross-platform gene-expression, computational methods on breast cancer subtyping in PALOMA-2 and PALLET studies.Maggie Chon U Cheang, Mothaffar Rimawi, Stephen Johnston, Samuel A Jacobs, Judith Bliss
NPJ Breast Cancer. 2024-06-29 - Correction: NSABP FB-10: a phase Ib/II trial evaluating ado-trastuzumab emtansine (T-DM1) with neratinib in women with metastatic HER2-positive breast cancer.Samuel A Jacobs, Ying Wang, Jame Abraham, Huichen Feng, Alberto J Montero
Breast Cancer Research. 2024-05-24 - NSABP FB-10: a phase Ib/II trial evaluating ado-trastuzumab emtansine (T-DM1) with neratinib in women with metastatic HER2-positive breast cancer.Samuel A Jacobs, Ying Wang, Jame Abraham, Huichen Feng, Alberto J Montero
Breast Cancer Research. 2024-04-22
Press Mentions
Generex Announces Collaboration with Merck to Evaluate KEYTRUDA® (Pembrolizumab) in Combination with AE37 in Patients with Triple-Negative Breast CancerJuly 31st, 2017
Grant Support
- Core--Clinical Research Services Clinical Trials OfficeNational Cancer Institute2005–2008
- Core--Protocol Review And Monitoring SystemNational Cancer Institute2004–2008
- Cancer Center Model For Early Phase Clinical TrialsNational Cancer Institute2003–2005
- Clinical Research Services Clinical Trials OfficeNational Cancer Institute2004
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
